Electronic WhatsApp evidence without authentication or independent corroboration cannot sustain an unexplained-investment addition based on third-part...
Mutual current-account transactions excluded from deemed dividend treatment where no fresh borrowing arose; unsupported unsecured-loan addition also f...
The ITAT upheld that payments to third-party clinical laboratories are pass-through costs and must be excluded from the assessee's cost base when computing operating margin for CSMM services; the assessee's adjusted margin was accepted at 13.71% (versus 10.34% prior). The Tribunal rejected benchmarking by reference to contract R&D companies and sustained deletion of additions based on improper comparables, and affirmed that marketing support services should not be compared with high-end contract R&D providers. Grounds of appeal by the Revenue were dismissed. The assessee's objection to the AO's exercise of jurisdiction under s.143(3) after 14 years was rejected.
The ITAT upheld that payments to third-party clinical laboratories are pass-through costs and must be excluded from the assessee's cost base when computing operating margin for CSMM services; the assessee's adjusted margin was accepted at 13.71% (versus 10.34% prior). The Tribunal rejected benchmarking by reference to contract R&D companies and sustained deletion of additions based on improper comparables, and affirmed that marketing support services should not be compared with high-end contract R&D providers. Grounds of appeal by the Revenue were dismissed. The assessee's objection to the AO's exercise of jurisdiction under s.143(3) after 14 years was rejected.
Note: It is a system-generated summary and is for quick reference only.
TaxTMI 
TaxTMI 
of 4828 
Join Channel 
